Advertisement

Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States

      Background

      Current consensus recommendations are to not initiate cervical cancer screening for immunocompetent adolescent females before 21 years of age. This is in part because of the very low rate of 0.8 per 100,000 new cervical cancer cases diagnosed among women aged between 20 to 24 years. Timely human papillomavirus vaccination further decreases the incidence of cervical cancer to 4 cases per 100,000 persons by the age of 28 years. Screening before 21 years of age has demonstrated no clear benefit in cancer risk reduction or outcomes. In addition, unindicated screening among adolescents can lead to patient harm and increasing costs to the healthcare system.

      Objective

      It is important to assess the rates of overutilization of cervical cancer screening and to identify areas where improvements have occurred and where further opportunities exist. This study aimed to assess the trends over time and the practice and provider factors associated with unindicated cervical cancer screening tests in adolescent females within the largest healthcare system in the state.

      Study Design

      Cross-sectional data from patients aged 13 to 20 years who underwent cervical cancer screening between January 1, 2012, and December 31, 2018, across a large multihospital health system were reviewed. All cervical cancer screening results were included. The incidence rate of unindicated screening was analyzed over 6-month intervals using the Poisson regression analysis.

      Results

      The study included data from 118 providers and 794 women. Among the 900 screening results, most (90%) were unindicated: 87% with unindicated cytology testing alone and 14% with unindicated human papillomavirus testing. Screening tests were collected from patients aged 13 to 20 years, many of whom had multiple unindicated cytology tests, with 25 patients having ≥3 tests before the age of 21 years. Most results of cytology testing were negative for intraepithelial lesion or malignancy (77%). Moreover, 52 invasive diagnostic or therapeutic procedures (49 colposcopies and 3 conizations) were performed, of which 45 (87%) followed an unindicated screening test. Between 2012 and 2018, the incidence rate of unindicated cytology decreased by 33% (12.6 to 8.5 unindicated cytology per 1000 encounters). The incidence rate of unindicated screening was lower in the academic setting than in the community setting (incidence rate ratio, 0.43; P<.01). Even with decreases in the overall rates of unindicated screening throughout the study period, there were still 58 unindicated screening tests performed in the final year of this study.

      Conclusion

      Despite substantial reductions in unindicated screening for women aged <21 years, there remained areas for improvement. Our data reflected practices of guideline nonadherence up to 7 years after the 2012 guideline. Now, with a new series of changes to the guidelines, which may be even more challenging for patients and providers, it is more important than ever to utilize evidence-based strategies to improve guideline dissemination and adherence.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fontham E.T.H.
        • Wolf A.M.D.
        • Church T.R.
        • et al.
        Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
        CA Cancer J Clin. 2020; 70: 321-346
        • Curry S.J.
        • Krist A.H.
        • et al.
        • US Preventive Services Task Force
        Screening for cervical cancer: US Preventive Services Task Force recommendation statement.
        JAMA. 2018; 320: 674-686
      1. ACOG Practice Bulletin no. 109: cervical cytology screening.
        Obstet Gynecol. 2009; 114: 1409-1420
        • Qin J.
        • Saraiya M.
        • Martinez G.
        • Sawaya G.F.
        Prevalence of potentially unnecessary bimanual pelvic examinations and Papanicolaou tests among adolescent girls and young women aged 15-20 years in the United States.
        JAMA Intern Med. 2020; 180: 274-280
        • Moscicki A.B.
        • Shiboski S.
        • Hills N.K.
        • et al.
        Regression of low-grade squamous intra-epithelial lesions in young women.
        Lancet. 2004; 364: 1678-1683
        • Lei J.
        • Ploner A.
        • Elfström K.M.
        • et al.
        HPV vaccination and the risk of invasive cervical cancer.
        N Engl J Med. 2020; 383: 1340-1348
        • Perkins R.B.
        • Anderson B.L.
        • Gorin S.S.
        • Schulkin J.A.
        Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists.
        Am J Prev Med. 2013; 45: 175-181
        • Oliveira C.R.
        • Hosier H.
        • Pate B.
        • Niccolai L.M.
        • Sheth S.S.
        • Vash-Margita A.
        Compliance with cervical cancer screening guidelines in young female patients: rates and trends of screening in New Haven County, CT.
        Am J Obstet Gynecol. 2019; 221: 530-532
        • Saslow D.
        • Solomon D.
        • Lawson H.W.
        • et al.
        American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.
        J Low Genit Tract Dis. 2012; 16: 175-204
        • Kyrgiou M.
        • Athanasiou A.
        • Paraskevaidi M.
        • et al.
        Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis.
        BMJ. 2016; 354: i3633
      2. Practice Bulletin No. 168: cervical cancer screening and prevention.
        Obstet Gynecol. 2016; 128: e111-e130
        • Oliveira C.R.
        • Niccolai P.
        • Ortiz A.M.
        • et al.
        Natural language processing for surveillance of cervical and anal cancer and precancer: algorithm development and split-validation study.
        JMIR Med Inform. 2020; 8: e20826
        • Moscicki A.B.
        • Flowers L.
        • Huchko M.J.
        • et al.
        Guidelines for cervical cancer screening in immunosuppressed women without HIV infection.
        J Low Genit Tract Dis. 2019; 23: 87-101
        • Perkins R.B.
        • Guido R.S.
        • Castle P.E.
        • et al.
        2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.
        J Low Genit Tract Dis. 2020; 24: 102-131
        • Foxx A.M.
        • Zhu Y.
        • Mitchel E.
        • Nikpay S.
        • Khabele D.
        • Griffin M.R.
        Cervical cancer screening and follow-up procedures in women age <21 years following new screening guidelines.
        J Adolesc Health. 2018; 62: 170-175
        • Becerra-Culqui T.A.
        • Lonky N.M.
        • Chen Q.
        • Chao C.R.
        Patterns and correlates of cervical cancer screening initiation in a large integrated health care system.
        Am J Obstet Gynecol. 2018; 218: 429.e1-429.e9
        • Teoh D.
        • Isaksson Vogel R.
        • Hultman G.
        • et al.
        Single health system adherence to 2012 cervical cancer screening guidelines at extremes of age and posthysterectomy.
        Obstet Gynecol. 2017; 129: 448-456
        • Qin J.
        • Saraiya M.
        • Martinez G.
        • Sawaya G.F.
        Prevalence of potentially unnecessary bimanual pelvic examinations and Papanicolaou tests among adolescent girls and young women aged 15-20 years in the United States.
        JAMA Intern Med. 2020; 180: 274-280
        • Hirth J.M.
        • Tan A.
        • Wilkinson G.S.
        • Berenson A.B.
        Compliance with cervical cancer screening and human papillomavirus testing guidelines among insured young women.
        Am J Obstet Gynecol. 2013; 209: 200.e1-200.e7
        • Min C.J.
        • Massad L.S.
        • Dick R.
        • Powell M.A.
        • Kuroki L.M.
        Assessing physician adherence to guidelines for cervical cancer screening and management of abnormal screening results.
        J Low Genit Tract Dis. 2020; 24: 337-342
        • Teoh D.
        • Hultman G.
        • DeKam M.
        • et al.
        Excess cost of cervical cancer screening beyond recommended screening ages or after hysterectomy in a single institution.
        J Low Genit Tract Dis. 2018; 22: 184-188
      3. CfMaM. Services. Baltimore (MD); 2016 Clinical Lab Fee Schedule. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files. Accessed July 29, 2021.

        • Vash-Margita A.
        • Kobernik E.K.
        • Flagler E.N.
        • Quint E.H.
        • Dalton V.K.
        National trends in cervical cancer screening in adolescents.
        J Pediatr Adolesc Gynecol. 2021; ([Epub ahead of print])
        • Clay J.M.
        • Daggy J.K.
        • Fluellen S.
        • Tucker Edmonds B.
        Patient knowledge and attitudes toward cervical cancer screening after the 2012 screening guidelines.
        Patient Educ Couns. 2019; 102: 411-415
        • Akinlotan M.
        • Bolin J.N.
        • Helduser J.
        • Ojinnaka C.
        • Lichorad A.
        • McClellan D.
        Cervical cancer screening barriers and risk factor knowledge among uninsured women.
        J Community Health. 2017; 42: 770-778
        • Lozman R.L.
        • Belcher A.
        • Sloand E.
        Does a 30-min quality improvement clinical practice meeting reviewing the recommended Papanicolaou test guidelines for adolescents improve provider adherence to guidelines in a pediatric primary care office?.
        J Am Assoc Nurse Pract. 2013; 25: 584-587
        • Choma K.
        • McKeever A.E.
        Cervical cancer screening in adolescents: an evidence-based internet education program for practice improvement among advanced practice nurses.
        Worldviews Evid Based Nurs. 2015; 12: 51-60
        • Langsjoen J.
        • Goodell C.
        • Castro E.
        • et al.
        Improving compliance with cervical cancer screening guidelines.
        Proc (Bayl Univ Med Cent). 2015; 28: 450-453